Report contents
At a glance
- Business model: Amgen sells branded biologics through insurers, PBMs and wholesalers, booking revenue net of estimated rebates. The strength is replacement in place: in Q2 2026 the six highlighted growth drivers rose 26% and supplied nearly 70% of product sales, while Enbrel fell 33% in FY2025. Medicare-set prices and biosimilar substitution shrink the base faster than volume offsets.
- Financial quality: Free cash flow beat net income in each of the last five fiscal years and capex has run near 5% of revenue, so FY2025 free cash flow of $8.10 billion is largely unforced. Capacity is thinner: liabilities were 88% of assets, interest absorbed about a quarter of FY2025 operating income, and $18.67 billion of goodwill sits against $11.69 billion of equity at June 30, 2026.
Business model
Business model: a mature portfolio replacing its own base
Amgen is a research-based biopharma manufacturer at a mature stage, mid-transition. It sells branded biologics and small molecules for inflammation (Enbrel, Otezla), bone disease (Prolia, Xgeva), cardiovascular risk (Repatha), rare disease (TEPEZZA, KRYSTEXXA) and supportive cancer care (Neulasta, Aranesp). The paying customer is rarely the patient. In the US, commercial insurers and Medicare, working through pharmacy benefit managers (PBMs, the intermediaries that trade formulary access for rebates), decide what is covered, and a small group of wholesalers takes title and ships to providers. Outside the US, government health systems set reimbursement directly. Amgen books product sales on shipment to distributors, net of estimated rebates, chargebacks and returns, so reported revenue is list price minus a large and estimated deduction.
Where the revenue comes from
The mix is the whole story, because the old base is shrinking. Amgen reported $36.8 billion of revenue in 2025, up 10%, and that total combines opposite trends. Enbrel sales fell 33% as net prices came under pressure, Xgeva declined, Prolia faces faster erosion as denosumab biosimilars spread, and Otezla was selected for Medicare price setting starting in 2027, which cuts expected cash flow years before any volume effect arrives. Growth now comes from Repatha, just over $3 billion in 2025 and up 36% after an August 2025 label expansion, and from the Horizon rare disease assets: TEPEZZA at $1.9 billion and KRYSTEXXA at $1.34 billion. Horizon-related expenses are also falling, which helped 2025 margins and suggests the acquired assets are now running as core business rather than being absorbed.
That rotation changes the economics. The profit pool is moving from primary-care-scale inflammation drugs toward specialist products with smaller patient populations, higher revenue per patient and more concentrated prescribing. Specialty products carry less exposure to the rebate-driven price war in large primary-care categories, but they also depend on narrower prescriber bases and, in TEPEZZA's case, on infusion capacity.
Price rather than volume is the binding constraint. Repatha's 36% growth looks like a volume story, and probably is: a broader label adds patients, while net price per prescription tends to fall as payers extract rebates for access. Medicare negotiation works differently. It is an administered price cut that extra volume cannot offset and that applies regardless of whether a rival product exists. Amgen does not disclose realized net price by product, so the price-versus-volume split has to be inferred from product revenue against prescription data and management commentary. That gap limits how precisely the mix shift can be modeled.
What protects the franchise
Distribution adds a second layer of estimation. US sales run through a handful of wholesalers, so reported growth can reflect their ordering patterns rather than patient starts, and the difference reverses in a later period. The gross-to-net accrual is the larger swing factor: rebates, chargebacks, copay support and returns are estimated every quarter, and small changes in those assumptions move reported revenue without any change in demand. For a company whose growth now rests on expensive specialty drugs with concentrated payer coverage, an accrual change and a demand shortfall can look identical for a quarter.
The protection around the portfolio is narrower than its breadth suggests. Patients stable on a chronic biologic rarely switch, and manufacturing scale and process know-how are real barriers to a biosimilar entrant. Once an interchangeable rival is approved and payers prefer it, though, price and share fall together. Denosumab is the clearest test, because Prolia and Xgeva face the substitution path Enbrel has already traveled. The counterweight is Amgen's ability to run large outcome trials that widen labels and defend reimbursement, visible in Repatha's cardiovascular data and in the Phase 3 program around MariTide, which now includes cardiovascular outcomes, heart failure and obstructive sleep apnea studies alongside weight management.
MariTide is option value, not current business. A successful Phase 3 would change the growth profile, but it says little about whether the existing portfolio can hold its revenue while that program matures.
The judgment that Amgen is a mature company replacing a shrinking base would be overturned if newer products covered legacy erosion at the company level for several consecutive quarters while gross-to-net deductions stabilized. Repatha, TEPEZZA, KRYSTEXXA and a subcutaneous TEPEZZA, if approved, are the assets that would have to do it.
Questions worth following
- Can TEPEZZA and KRYSTEXXA become a durable second growth pillar?
Rare disease is the main internal offset to Enbrel, Prolia and Otezla erosion. If these two products keep growing at specialist rates, Amgen's revenue base stabilizes on higher per-patient economics; if they plateau, the replacement burden falls almost entirely on Repatha and on pipeline assets that have not launched.
Financial quality
Financial quality: cash is real, equity is thin
Amgen turns most of its reported profit into cash. Free cash flow beat net income in each of the last five fiscal years, and capex has stayed near 5% of revenue, so the business does not need heavy reinvestment to keep the cash coming. The balance sheet carries the risk. Liabilities equal 88% of assets, interest expense absorbed a quarter of FY2025 operating income, and $18.7 billion of goodwill sits against $11.7 billion of equity.
The annual record: margins recovered and cash kept pace
| USD bn unless noted | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | H1 FY2026 | Assessment |
|---|---|---|---|---|---|---|---|
| Revenue | 26.0 | 26.3 | 28.2 | 33.4 | 36.7 | 18.7 | Adequate (11.8% CAGR) |
| Gross margin % | 75.2 | 75.7 | 70.0 | 61.5 | 70.8 | 70.2 | Strong |
| Net margin % | 22.7 | 24.9 | 23.8 | 12.2 | 21.0 | 22.5 | Strong |
| ROE % | 73.2 | 126.5 | 135.8 | 67.6 | 106.1 | 35.9 | Not meaningful |
| ROA % | 9.5 | 10.4 | 8.3 | 4.3 | 8.5 | 4.5 | Adequate |
| Liabilities / assets % | 89.0 | 94.4 | 93.6 | 93.6 | 90.4 | 87.8 | Very weak band |
| Cash / short-term debt (x) | 88.8 | 4.8 | 7.6 | 3.4 | 2.0 | 2.6 | Adequate |
| Interest expense | 1.20 | 1.41 | 2.88 | 3.16 | 2.75 | 1.33 | Demanding |
| Operating cash flow | 9.26 | 9.72 | 8.47 | 11.49 | 9.96 | 6.19 | Strong |
| Free cash flow | 8.38 | 8.79 | 7.36 | 10.39 | 8.10 | 4.97 | Strong |
| FCF / net income (x) | 1.42 | 1.34 | 1.10 | 2.54 | 1.05 | 1.18 | Exceptional |
| Capex / revenue % | 3.4 | 3.5 | 3.9 | 3.3 | 5.1 | 6.5 | Asset-light |
*Six months ended June 30, 2026; flow items cover two quarters, balance-sheet items are period-end, and ROE/ROA are not annualized.
Revenue compounded at 11.8% a year from FY2022 to FY2025, with FY2024 up 18.6% as the Horizon Therapeutics acquisition came in. The FY2024 collapse in gross margin (61.5%) and net margin (12.2%) reversed the following year to 70.8% and 21.0%, which fits amortization of acquired intangibles rather than a pricing breakdown. Amgen said in its August 4, 2026 release that second-quarter revenue rose 10% to $10.1 billion, GAAP operating margin reached 36.8% (up 6.5 points) and non-GAAP operating margin slipped half a point to 48.4%. The $1.1 billion quarterly gap between the two is largely non-cash amortization, and it explains why free cash flow has run at 1.05–1.34x net income in ordinary years.
Return on equity flatters a thin capital base
A 135.8% ROE in FY2023 and 106% in FY2025 measure almost nothing. Equity never exceeded $12 billion because buybacks and deal spending keep it there. Return on assets of 8.5% in FY2025 and about $9 billion of after-tax operating income on roughly $81 billion of assets net of cash imply a return on invested capital near 11%. That is respectable for a large drugmaker running 0.40 asset turns, and it is the number to hold Amgen to; each further buyback lowers equity and lifts reported ROE without changing the business.
Quarterly: cash flow improves, borrowings creep up
| USD bn unless noted | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Assessment | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.15 | 9.17 | 9.56 | 9.90 | 8.62 | 10.05 | Adequate | Improving |
| Gross margin % | 63.6 | 67.2 | 67.7 | 81.9 | 68.1 | 72.0 | Strong | Volatile |
| Net income | 1.73 | 1.43 | 3.22 | 1.33 | 1.82 | 2.38 | Adequate | Lumpy |
| Operating cash flow | 1.39 | 2.28 | 4.68 | 1.60 | 2.19 | 4.00 | Strong | Improving |
| Free cash flow | 0.98 | 1.91 | 4.25 | 0.96 | 1.48 | 3.49 | Strong | Improving |
| Total assets | 89.37 | 87.90 | 90.14 | 90.59 | 92.50 | 95.64 | — | Rising |
| Total liabilities | 83.16 | 80.47 | 80.52 | 81.93 | 83.31 | 83.95 | Very weak band | High, stable |
| Total equity | 6.21 | 7.43 | 9.62 | 8.66 | 9.19 | 11.69 | Thin | Improving |
| Goodwill | 18.64 | 18.67 | 18.68 | 18.68 | 18.67 | 18.67 | Exceeds equity | Flat |
| Cash | 8.81 | 8.03 | 9.45 | 9.13 | 12.04 | 13.99 | Adequate | Rising |
| Short-term debt | 3.37 | 2.44 | 2.15 | 4.60 | 5.44 | 5.45 | Manageable | Rising |
These are standalone quarters; the four FY2025 periods sum to the reported annual totals. Amgen attributed the rise in second-quarter 2026 free cash flow to $3.5 billion from $1.9 billion mainly to the final repatriation tax payment falling in the 2025 quarter and to working-capital timing, so the first-half comparison of $4.97 billion against $2.89 billion overstates the underlying gain.
What the cash flow has to cover
Interest is the first claim. At $2.75 billion in FY2025, it consumed 26% of operating income, and coverage has fallen from 6.4x in FY2021 to 3.9x as debt rose with Horizon. Less coverage matters more in a price-deflation cycle: Medicare Part D price setting took effect January 1, 2026 and already shows up in Enbrel's 22% lower net selling price.
Volume is what has to outrun price. The six growth drivers Amgen highlights grew 26% and produced nearly 70% of second-quarter product sales, while Prolia fell 32% (20% lower volume, 12% lower price) and Otezla fell 21%. If volume growth keeps winning, the revenue base and the 70% gross margin hold. If the eroding products fall faster than the launches ramp, cash flow and coverage tighten together.
Distributions have leaned on the balance sheet. FY2025 financing outflows were $10.86 billion against $8.10 billion of free cash flow, and short-term debt climbed from $2.15 billion in September 2025 to $5.45 billion by June 2026 even as cash rose to $14.0 billion. The company can clearly service this; the question is whether the buyback is funded by cash generation or by rolling short-term borrowings.
Three things to check next
- The Enbrel accrual release. Enbrel sales fell only 4% because a 22% price decline was offset by a 16-point favorable change to estimated sales deductions. Watch the sales-deduction balance against gross sales to see whether this was a catch-up or a permanently lower reserve. The fourth-quarter 2025 gross margin of 81.9%, against 63–68% earlier in the year, is another year-end item that needs explaining.
- Goodwill against thin equity. Goodwill of $18.67 billion is 1.6x total equity. Impairment testing rests on Horizon's rare-disease assets, where TEPEZZA, KRYSTEXXA, UPLIZNA and TAVNEOS are all growing at double digits, offsetting denosumab and Otezla erosion. A write-down would not touch cash but would land hard on equity this thin.
- Short-term debt and cash both rising. Borrowings due within a year more than doubled in three quarters while cash built to $14.0 billion. Whether that reflects pre-funding of maturities or routine liquidity management determines how much refinancing risk the leverage ratio actually represents.
Questions worth following
- Can Amgen fund buybacks and dividends from free cash flow alone?
FY2025 financing outflows of $10.86 billion exceeded free cash flow of $8.10 billion, and short-term debt more than doubled in three quarters. Whether distributions are covered by cash generation or by borrowings decides whether leverage falls or compounds from an already thin equity base.
- Are Amgen's sales-deduction accruals flattering reported product sales?
Enbrel sales fell just 4% in the second quarter of 2026 after a 22% drop in net selling price, with a 16-point favorable change in estimated sales deductions doing the offsetting. If reserve releases rather than demand are holding revenue up, the earnings base is less durable than the margin suggests.
- Will eroding Prolia and Otezla sales force a goodwill write-down?
Goodwill of $18.67 billion is 1.6x total equity of $11.69 billion, so an impairment would hit an already thin capital base and could constrain buybacks. Whether the Horizon rare-disease assets keep growing fast enough to carry that value is the swing factor.
Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.
Continue reading the full report
- Key risksWhat could break the investment case
- Valuation and margin of safetyWhat the current price assumes, and how much room for error it leaves
- SummaryOur overall judgement and what to watch next
Free to sign up · 20 research points · unlocking this report uses 10
20 points cover 2 full reports. No card needed.
Research reflects its generation date. Preview the first two modules.
More on Amgen Inc
Amgen Inc
Business, moat and key questions
Open company page